Intraventricular Delivery and CRISPR-Cas9 Disruption of PD-1 is Required for CAR T-cell Efficacy in Glioblastoma

被引：0
|
作者：
Choi, Bryan D.
Yu, Xiaoling
Nahed, Brian V.
Cahill, Daniel P.
Curry, William T.
Carter, Bob S.
Maus, Marcela V.
机构：
来源：
NEUROSURGERY | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
823
引用
收藏
页码：286 / 286
页数：1
相关论文
共 50 条
  • [41] Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention
    Min Li
    Ya-Nan Fan
    Zhi-Yao Chen
    Ying-Li Luo
    Yu-Cai Wang
    Zhe-Xiong Lian
    Cong-Fei Xu
    Jun Wang
    Nano Research, 2018, 11 : 6270 - 6282
  • [42] AN OPTIMIZED FULLY RNA-BASED PLATFORM FOR CRISPR/CAS9-MEDIATED DISRUPTION OF NATIVE T-CELL RECEPTORS FOR T-CELL THERAPIES
    Flumens, D.
    Luyckx, K.
    Janssens, I.
    Campillo-Davo, D.
    Lion, E.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A27 - A28
  • [43] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of umbilical cord blood - derived T cells engineered to target NY-ESO-1
    Shao, J.
    Zhao, Y.
    Su, S.
    Xu, Q.
    Meng, F.
    Wei, J.
    Qian, X.
    Zou, Z.
    Liu, B.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 390 - 391
  • [44] Using advanced CRISPR-Cas9 functional genetics to model and probe T-cell acute lymphoblastic leukemia (T-ALL)
    Schinke, M.
    Kleppa, M. J.
    Poetzsch, J.
    Heckl, D.
    Heuser, M.
    Schambach, A.
    Schwarzer, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 137 - 137
  • [45] Novel Strategies to Enhance the Efficacy of CAR T-cell Immunotherapy in Glioblastoma
    Brosque, Alina
    Rousso-Noori, Liat
    Tarab-Ravski, Dana
    Nahmias, Shani
    Engel, Yarden
    Berger, Michael
    Machluf, Marcelle
    Peer, Dan
    Friedmann-Morvinski, Dinorah
    MOLECULAR THERAPY, 2023, 31 (04) : 570 - 570
  • [46] Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
    Tipanee, Jaitip
    Samara-Kuko, Ermira
    Gevaert, Thierry
    Chuah, Marinee K.
    VandenDriessche, Thierry
    MOLECULAR THERAPY, 2022, 30 (10) : 3155 - 3175
  • [47] PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis
    Blobner, Jens
    Dengler, Laura
    Eberle, Constantin
    Herold, Julika J.
    Xu, Tao
    Beck, Alexander
    Muehlbauer, Anton
    Mueller, Katharina J.
    Teske, Nico
    Karschnia, Philipp
    van den Heuvel, Dominic
    Schallerer, Ferdinand
    Ishikawa-Ankerhold, Hellen
    Thon, Niklas
    Tonn, Joerg-Christian
    Subklewe, Marion
    Kobold, Sebastian
    Harter, Patrick N.
    Buchholz, Veit R.
    von Baumgarten, Louisa
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [48] NANOPARTICLE DELIVERY OF PD-L1 CRISPR/CAS9 PLASMID DNA FOR ANTI-GLIOBLASTOMA IMMUNOTHERAPY
    Fierro, Javier
    Tran, An
    Factoriza, Chris
    Chin, Brandon
    Dou, Huanyu
    NEURO-ONCOLOGY, 2020, 22 : 216 - 216
  • [49] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
    Lauren Giuffrida
    Kevin Sek
    Melissa A. Henderson
    Junyun Lai
    Amanda X. Y. Chen
    Deborah Meyran
    Kirsten L. Todd
    Emma V. Petley
    Sherly Mardiana
    Christina Mølck
    Gregory D. Stewart
    Benjamin J. Solomon
    Ian A. Parish
    Paul J. Neeson
    Simon J. Harrison
    Lev M. Kats
    Imran G. House
    Phillip K. Darcy
    Paul A. Beavis
    Nature Communications, 12
  • [50] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
    Giuffrida, Lauren
    Sek, Kevin
    Henderson, Melissa A.
    Lai, Junyun
    Chen, Amanda X. Y.
    Meyran, Deborah
    Todd, Kirsten L.
    Petley, Emma, V
    Mardiana, Sherly
    Molck, Christina
    Stewart, Gregory D.
    Solomon, Benjamin J.
    Parish, Ian A.
    Neeson, Paul J.
    Harrison, Simon J.
    Kats, Lev M.
    House, Imran G.
    Darcy, Phillip K.
    Beavis, Paul A.
    NATURE COMMUNICATIONS, 2021, 12 (01)
12345